肯尼亚孕期暴露于HIV暴露前预防与出生、生长及社会情绪发育结局的前瞻性队列研究
该前瞻性队列研究分析了肯尼亚4063名孕妇,其中558名(13.7%)孕期使用暴露前预防。随访至产后36个月,发现孕期暴露前预防暴露与自然流产、死产、早产、新生儿死亡、婴儿生长及社会情绪发育无显著差异,支持口服暴露前预防在孕期使用的安全性。
要点
- 孕期暴露前预防暴露未增加流产、死产、早产或新生儿死亡风险(所有p>0.05)。
- 暴露前预防暴露与6周、6个月、9个月婴儿身长或体重无差异(所有p>0.05)。
- 暴露前预防暴露与24、30、36个月ASQ-SE评分无关联(p=0.12、0.75、0.81)。
核心结论
- 在3年随访中,孕期暴露前预防暴露状态与不良出生、婴儿或儿童结局无显著差异。
- 这些数据支持先前研究显示的孕期口服暴露前预防使用的安全性。
研究设计与样本
- 前瞻性队列研究,分析暴露前预防实施用于产前保健研究(NCT03070600)的数据。
- 在肯尼亚西部20家母婴健康诊所招募孕妇,随访至产后9个月,扩展队列随访至产后36个月。
- 共纳入4063名孕妇,其中558名(13.7%)孕期使用暴露前预防,起始中位孕周26周(IQR 22-31),孕期使用中位时长9.6周(5.7-15.0)。
- 通过干血斑中替诺福韦二磷酸浓度确认部分参与者的孕期暴露前预防暴露。
主要发现
- 与未暴露妊娠相比,暴露前预防暴露妊娠的流产、死产、早产或新生儿死亡无差异(所有p>0.05)。
- 暴露前预防暴露与未暴露儿童在6周、6个月、9个月的身长或体重无差异(所有p>0.05),包括体重不足、生长迟缓和消瘦。
- 按暴露前预防起始孕期或使用时长分层分析,以及24、30、36个月子集分析,结果相似。
- 暴露前预防暴露与24个月(p=0.12)、30个月(p=0.75)、36个月(p=0.81)的ASQ-SE评分无关联。
- 在可定量检测孕期替诺福韦二磷酸暴露的肯尼亚个体中,不良围产期和婴儿结局无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As pre-exposure prophylaxis (PrEP) implementation continues to scale up among pregnant people, accruing safety data following prenatal PrEP exposure remains important. In this study, we aimed to evaluate the relationship between prenatal PrEP exposure and birth and infant or child outcomes. METHODS: This prospective cohort study analysed data from the PrEP Implementation for Mothers in Antenatal Care study (NCT03070600). Participants were eligible for inclusion if they were currently pregnant, not currently using PrEP, were aged 15 years or older, planned to remain in the study area, were not enrolled in other studies, and did not have HIV or tuberculosis. Participants enrolled during pregnancy at 20 maternal and child health clinics in western Kenya and were followed up until 9 months postpartum. Those who reported taking PrEP at any antenatal visits were identified as prenatally PrEP exposed. In an extension cohort, participants and their children were followed up until 36 months postpartum. Infant anthropometry and social-emotional development using the Ages and Stages Questionnaire (ASQ-SE), second edition were assessed by trained study nurses. Among a subset of participants, we confirmed prenatal PrEP exposure using tenofovir diphosphate concentrations in dried blood spots. Perinatal outcomes (birth, growth, and neurodevelopment) were the primary outcomes assessed. FINDINGS: Between Jan 15, 2018, and Jul 31, 2019, 4063 female individuals were enrolled and included in the analysis, of whom 558 (13·7%) used PrEP during pregnancy, initiating at a median of 26 weeks' gestation (IQR 22-31) for a median duration of 9·6 weeks in pregnancy (5·7-15·0). Compared with PrEP-unexposed pregnancies, there was no difference in pregnancy loss (ie, miscarriage), stillbirth, preterm birth, or neonatal death among PrEP exposed pregnancies (all p>0·05). There were no differences in infant length or weight at 6 weeks, 6 months, and 9 months (all p>0·05) between children with and without prenatal PrEP exposure, including underweight, stunting, and wasting. Results were similar when analysed separately by trimester of PrEP initiation and duration on PrEP, and in a subset at 24 months, 30 months, and 36 months. Prenatal PrEP exposure was not associated with ASQ-SE scores at 24-months (p=0·12), 30-months (p=0·75), or 36-months (p=0·81). No differences in adverse perinatal and infant outcomes were found among Kenyan individuals with quantifiable prenatal tenofovir diphosphate exposure. INTERPRETATION: We found no significant differences in adverse birth or infant or child outcomes for 3 years of follow-up by prenatal PrEP exposure status. These data support findings from previous studies that demonstrate the safety of oral PrEP use during pregnancy. FUNDING: The National Institutes of Health, National Institute of Allergy and Infectious Disease; Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Nursing Research; the University of Washington's Center for AIDS Research Behavioral Sciences Core and Biometrics Core; and the Global Center for the Integrated Health of Women, Adolescents, and Children. TRANSLATION: For the Swahili translation of the abstract see Supplementary Materials section.
引用
- Gómez L, Kinuthia J, Abuna F, et al. Prenatal exposure to HIV pre-exposure prophylaxis and birth, growth, and social-emotional developmental outcomes throughout early childhood in Kenya: a prospective cohort study. Lancet Glob Health. 2025. PMID: 40021305. doi:10.1016/S2214-109X(24)00471-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。